Wood Marci, Rymarchyk Stacia, Zheng Song, Cen Yana
Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 261 Mountain View Drive, Colchester, VT 05446, USA.
Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 261 Mountain View Drive, Colchester, VT 05446, USA.
Arch Biochem Biophys. 2018 Jan 15;638:8-17. doi: 10.1016/j.abb.2017.12.009. Epub 2017 Dec 9.
SIRT6 is an epigenetic modification enzyme that regulates gene transcription through its deacetylase activity. In addition to histone protein, SIRT6 also modify other proteins and enzymes, some of which are central players in metabolic reprogramming and aging process. Therefore, SIRT6 has emerged as a therapeutic target for the treatment of metabolic disorder and age-related diseases. Here, we report that SIRT6 deacetylates lysine 382 of p53 in short synthetic peptide sequence and in full length p53. Further studies showed that the deacetylation of H3K9Ac and p53K382Ac are insensitive to nicotinamide inhibition, but are sensitive to trichostatin A (TSA) inhibition. Detailed kinetic analysis revealed that TSA competes with the peptide substrate for inhibition, and this inhibition is unique to SIRT6 in the sirtuin family. Taken together, this study not only suggests potential roles of SIRT6 in regulating apoptosis and stress resistance via direct deacetylation of p53, but also provides lead compound for the development of potent and selective SIRT6 inhibitors.
SIRT6是一种表观遗传修饰酶,通过其脱乙酰酶活性调节基因转录。除组蛋白外,SIRT6还修饰其他蛋白质和酶,其中一些是代谢重编程和衰老过程的核心参与者。因此,SIRT6已成为治疗代谢紊乱和年龄相关疾病的治疗靶点。在此,我们报告SIRT6在短合成肽序列和全长p53中使p53的赖氨酸382脱乙酰化。进一步研究表明,H3K9Ac和p53K382Ac的脱乙酰化对烟酰胺抑制不敏感,但对曲古抑菌素A(TSA)抑制敏感。详细的动力学分析表明,TSA与肽底物竞争抑制,这种抑制在sirtuin家族中是SIRT6独有的。综上所述,本研究不仅提示SIRT6通过直接使p53脱乙酰化在调节细胞凋亡和应激抗性中的潜在作用,还为开发强效和选择性SIRT6抑制剂提供了先导化合物。